Interleukin-6 as a therapeutic target in spondylarthritis: Comment on the article by Tanaka et al


  • Daniel Wendling MD, PhD

    1. University of Franche-ComtéBesançon, France
    Search for more papers by this author
    • Dr. Wendling has received consulting fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, BMS, Wyeth, Schering-Plough, Roche-Chugai, Nordic Pharma, Sanofi-Aventis, and Servier, and was an investigator in the tocilizumab trial OPTION in rheumatoid arthritis.

No abstract is available for this article.